US 20220023420A1

(19) United States

(12) Patent Application Publication

SABZEVARI et al.

(10) Pub. No.: US 2022/0023420 A1

(43) Pub. Date: Jan. 27, 2022

(54) **FUSION CONSTRUCTS AND METHODS OF USING THEREOF**

(71) Applicant: **Precigen, Inc.**, GERMANTOWN, MD (US)

(72) Inventors: **Helen SABZEVARI**, GERMANTOWN, MD (US); **Simon METENOU**, GERMANTOWN, MD (US); **Chang Hung CHEN**, GERMANTOWN, MD (US); **Rutul SHAH**, GERMANTOWN, MD (US)

(73) Assignee: **Precigen, Inc.**, GERMANTOWN, MD (US)

(21) Appl. No.: **17/305,577**

(22) Filed: **Jul. 9, 2021**

Related U.S. Application Data

(60) Provisional application No. 63/050,393, filed on Jul. 10, 2020, provisional application No. 63/173,902, filed on Apr. 12, 2021.

Publication Classification

(51) **Int. Cl.**

A61K 39/395	(2006.01)
C07K 16/30	(2006.01)
C07K 16/28	(2006.01)
C07K 14/71	(2006.01)
A61K 38/17	(2006.01)
A61K 38/20	(2006.01)
A61K 35/17	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 39/39558*** (2013.01); ***A61K 35/17*** (2013.01); ***C07K 16/30*** (2013.01); ***C07K 16/2884*** (2013.01); ***C07K 14/71*** (2013.01); ***C07K 16/2875*** (2013.01); ***C07K 16/2878*** (2013.01); ***C07K 16/2818*** (2013.01); ***C07K 16/2866*** (2013.01); ***C07K 16/2857*** (2013.01); ***C07K 16/2896*** (2013.01); ***C07K 16/3069*** (2013.01); ***C07K 16/2863*** (2013.01); ***C07K 16/2887*** (2013.01); ***A61K 38/179*** (2013.01); ***A61K 38/1793*** (2013.01); ***A61K 38/2086*** (2013.01); ***C07K 16/3092*** (2013.01)

(57) **ABSTRACT**

A fusion protein comprising: a first component comprising an antibody, or a fragment or variant thereof; and a second component comprising a cytokine trap or an adenosine deaminase or a fragment or variant thereof. In certain embodiments, the antibody is an anti-PD-1 antibody. In certain embodiments, the antibody binds to a tumor antigen, for example a MUC16 or MUC1 antigen. In certain embodiments, the cytokine trap is a TGF-β trap. A polynucleotide encoding such a fusion protein and a vector comprising such a polynucleotide. A composition comprising the fusion protein. A method of using the composition, including in the treatment of cancer.

Specification includes a Sequence Listing.